ROSEN, NATIONALLY RECOGNIZED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MREO

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding its clinical studies [1]. Group 1: Class Action Details - The class action pertains to Mereo ADSs purchased between June 5, 2023, and December 26, 2025, with a lead plaintiff deadline set for April 6, 2026 [1]. - Investors who purchased Mereo ADSs during the specified period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][7]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by the April 6, 2026 deadline [3]. Group 3: Case Background - The lawsuit claims that Mereo BioPharma provided investors with optimistic statements regarding the Phase 3 Orbit and COSMIC studies for setrusumab in treating Osteogenesis Imperfecta (OI), suggesting confidence in the drug's efficacy [5]. - However, the defendants allegedly concealed material adverse facts, as neither study achieved its primary endpoints, leading to artificially inflated prices for Mereo's ADSs [6].